Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about CIRCADIAN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | CIRCADIAN |
Knowledge base pages for this entity
graph TD
CIRCADIAN["CIRCADIAN"]
CIRCADIAN -->|"interacts"| Melatonin["Melatonin"]
CIRCADIAN ---|"co-discussed"| LIPID_METABOLISM["LIPID METABOLISM"]
CIRCADIAN ---|"co-discussed"| NEURON["NEURON"]
CIRCADIAN ---|"co-discussed"| NEURONS["NEURONS"]
CIRCADIAN ---|"co-discussed"| SLEEP["SLEEP"]
CIRCADIAN ---|"co-discussed"| STING["STING"]
Melatonin -->|"activates"| CIRCADIAN
ANGIOGENESIS["ANGIOGENESIS"] ---|"co-discussed"| CIRCADIAN
AKT["AKT"] ---|"co-discussed"| CIRCADIAN
ALZHEIMER["ALZHEIMER"] ---|"co-discussed"| CIRCADIAN
ALZHEIMER_S["ALZHEIMER'S"] ---|"co-discussed"| CIRCADIAN
ASTROCYTE["ASTROCYTE"] ---|"co-discussed"| CIRCADIAN| Target | Relation | Type | Str |
|---|---|---|---|
| Melatonin | interacts_with | entity | 0.70 |
| ENDOTHELIAL | co_discussed | entity | 0.50 |
| CYTOKINE | co_discussed | entity | 0.50 |
| MACROPHAGE | co_discussed | entity | 0.50 |
| OCLN | co_discussed | entity | 0.50 |
| TNF | co_discussed | entity | 0.50 |
| MICROGLIA | co_discussed | entity | 0.50 |
| GLYMPHATIC | co_discussed | entity | 0.50 |
| TAU | co_discussed | entity | 0.50 |
| CORTEX | co_discussed | entity | 0.50 |
| PREFRONTAL | co_discussed | entity | 0.50 |
| SCHIZOPHRENIA | co_discussed | entity | 0.50 |
| HISTONE | co_discussed | entity | 0.50 |
| CR1 | co_discussed | entity | 0.50 |
| PINK1 | co_discussed | entity | 0.50 |
| GBA | co_discussed | entity | 0.50 |
| GASDERMIN | co_discussed | entity | 0.50 |
| PYROPTOSIS | co_discussed | entity | 0.50 |
| PROTEOSTASIS | co_discussed | entity | 0.50 |
| PARP1 | co_discussed | entity | 0.50 |
| MITOCHONDRIAL DYSFUNCTION | co_discussed | entity | 0.50 |
| PERICYTE | co_discussed | entity | 0.50 |
| PERICYTES | co_discussed | entity | 0.50 |
| STROKE | co_discussed | entity | 0.50 |
| SEROTONERGIC | co_discussed | entity | 0.50 |
| LC3 | co_discussed | entity | 0.50 |
| DEPRESSION | co_discussed | entity | 0.50 |
| EPIGENETIC | co_discussed | entity | 0.50 |
| DOPAMINERGIC | co_discussed | entity | 0.50 |
| GABA | co_discussed | entity | 0.50 |
| GABAergic | co_discussed | entity | 0.50 |
| NEURODEGENERATION | co_discussed | entity | 0.50 |
| HUNTINGTON | co_discussed | entity | 0.50 |
| PARKINSON | co_discussed | entity | 0.50 |
| PARKINSON'S | co_discussed | entity | 0.50 |
| NEUROINFLAMMATION | co_discussed | entity | 0.50 |
| NEURON | co_discussed | cell_type | 0.50 |
| DEMENTIA | co_discussed | entity | 0.50 |
| FRONTOTEMPORAL | co_discussed | entity | 0.50 |
| MITOCHONDRIA | co_discussed | entity | 0.50 |
| MTOR | co_discussed | entity | 0.50 |
| T CELLS | co_discussed | entity | 0.50 |
| COMPLEMENT | co_discussed | entity | 0.50 |
| HIPPOCAMPUS | co_discussed | entity | 0.50 |
| SIRT1 | co_discussed | entity | 0.50 |
| OXIDATIVE STRESS | co_discussed | entity | 0.50 |
| GPX4 | co_discussed | entity | 0.50 |
| SENESCENCE | co_discussed | entity | 0.50 |
| GLUTAMATE | co_discussed | entity | 0.50 |
| SUBSTANTIA NIGRA | co_discussed | entity | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Melatonin | activates | entity | 0.70 |
| Melatonin | inhibits | entity | 0.70 |
| Melatonin | regulates | entity | 0.70 |
| Melatonin | interacts_with | entity | 0.70 |
| ASTROCYTES | contributes_to | entity | 0.50 |
| AMYGDALA | co_discussed | entity | 0.50 |
| BBB | co_discussed | entity | 0.50 |
| ASTROCYTES | co_discussed | entity | 0.50 |
| APP | co_discussed | entity | 0.50 |
| CHOLINERGIC | co_discussed | entity | 0.50 |
| AMPK | co_discussed | entity | 0.50 |
| CDK5 | co_discussed | entity | 0.50 |
| BLOOD-BRAIN BARRIER | co_discussed | entity | 0.50 |
| ANGIOGENESIS | co_discussed | entity | 0.50 |
| APOE | co_discussed | entity | 0.50 |
| AUTOPHAGY | co_discussed | entity | 0.50 |
| CALCIUM SIGNALING | co_discussed | entity | 0.50 |
| AXON | co_discussed | entity | 0.50 |
| AKT | co_discussed | entity | 0.50 |
| ALZHEIMER | co_discussed | entity | 0.50 |
| ALZHEIMER'S | co_discussed | entity | 0.50 |
| ASTROCYTE | co_discussed | entity | 0.50 |
| AQP4 | co_discussed | entity | 0.50 |
| APOPTOSIS | co_discussed | entity | 0.50 |
| BDNF | co_discussed | entity | 0.50 |
| ALS | co_discussed | entity | 0.50 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Circadian gene expression effects of SD vs ketamine | exploratory | depression | 0.950 | 0.00 | C57BL/6J mice | proposed | N/A |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| CLOCK/BMAL1 regulation of ICC autophagy in GERD model | exploratory | gastroesophageal reflux diseas | 0.900 | 0.00 | primary esophageal interstitia | proposed | N/A |
| Ketogenic diet efficacy in diet-induced obese mice | validation | obesity, metabolic disease | 0.900 | 0.00 | C57BL/6J diet-induced obese mi | proposed | N/A |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Circadian Dysfunction as Driver of Neurodegeneration | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep Disruption and Alzheimer's Disease — mechanism and intervention | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Respiratory Network Interaction in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Proposed experiment from debate on Astrocytes adopt A1 (neurotoxic) an | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Epigenetic clocks and biological ag | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Experiment Index | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Macroautophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| N-of-1 Clinical Trial Design for CBS/PSP | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Normal Aging to Alzheimer's Disease Transition Trigger — Identifying t | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Autophagy Enhancement Drug Screening for Neurodegeneration | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| BMAL1-HIF2A heterodimer modulates circadian variations of myocardial injury. [PMID:40269168] | Ruan W, Li T, Bang IH, Lee J, Deng W, Ma | Nature | 2025 | 1 |
| Obstructive sleep apnea syndrome, orexin, and sleep-wake cycle: The link with th [PMID:39864923] | Fernandes M, Liguori C | Handb Clin Neurol | 2025 | 1 |
| From geroscience to precision geromedicine: Understanding and managing aging. [PMID:40250404] | Kroemer G, Maier AB, Cuervo AM, Gladyshe | Cell | 2025 | 1 |
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Circadian Influences on Brain Lipid Metabolism and Neurodegenerative Diseases. [PMID:39728504] | Hussain Y, Dar MI, Pan X | Metabolites | 2024 | 1 |
| Circadian rhythm regulates the function of immune cells and participates in the [PMID:38678017] | Zeng Y, Guo Z, Wu M, Chen F, Chen L | Cell Death Discov | 2024 | 1 |
| BMAL1 involved in autophagy and injury of thoracic aortic endothelial cells of r [PMID:37086572] | Chunli Yang, Ziwei Deng, Qihang Zeng, Xi | Biochemical and biophysical re | 2023 | 1 |
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress di [PMID:33285346] | Cénat JM, Blais-Rochette C, Kokou-Kpolou | Psychiatry Res | 2021 | 1 |
| Improved T-cell Receptor Diversity Estimates Associate with Survival and Respons [PMID:33177107] | Bortone DS, Woodcock MG, Parker JS, Vinc | Cancer Immunol Res | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Circadian Clock Regulation on Lipid Metabolism and Metabolic Diseases. [PMID:32705594] | Pan X, Mota S, Zhang B | Adv Exp Med Biol | 2020 | 1 |
| Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Seque [PMID:32822576] | Maynard A, McCoach CE, Rotow JK, Harris | Cell | 2020 | 1 |
| The Ca(2+) Sensor SCaBP3/CBL7 Modulates Plasma Membrane H(+)-ATPase Activity and [PMID:30962395] | Yang Y, Wu Y, Ma L, Yang Z, Dong Q, Li Q | Plant Cell | 2019 | 1 |
| Spatiotemporal profile of postsynaptic interactomes integrates components of com [PMID:28671696] | Li J, Zhang W, Yang H, Howrigan DP, Wilk | Nat Neurosci | 2017 | 1 |
| Core Concept: The Internet of Things and the explosion of interconnectivity. [PMID:27702874] | Ornes S | Proc Natl Acad Sci U S A | 2016 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Impact of preinterventional plaque composition and eccentricity on late-acquired [PMID:22936019] | Sato T, Kameyama T, Noto T, Nozawa T, In | Coron Artery Dis | 2012 | 1 |
| Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and T [PMID:41833042] | ["Lyu G", "Li D"] | CNS & neurological disorders d | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning CIRCADIAN in their description or question text
Score: 0.712 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian Glymphatic Rescue Therapy (Melatonin-focused) starts from the claim that modulating MT
Score: 0.662 · unknown disease · 2026-04-04
## Mechanistic Overview Circadian-Metabolic Microglial Reprogramming starts from the claim that modulating CLOCK, BMAL1,
Score: 0.606 · metabolic-neuroscience · 2026-04-16
**Molecular Mechanism and Rationale** The circadian-gated ketone window hypothesis centers on the orchestrated regulati
Score: 0.585 · unknown disease · 2026-04-26
Evening administration of 0.5-1mg melatonin 2-3 hours before dim light melatonin onset maximizes circadian entrainment a
Score: 0.566 · neuroinflammation · 2026-04-21
## **Molecular Mechanism and Rationale** The molecular mechanism underlying this hypothesis centers on the stabilizatio
Score: 0.557 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian-Gated Maresin Biosynthesis Amplification starts from the claim that modulating ALOX12
Score: 0.543 · neurodegeneration · 2026-04-02
## Mechanistic Overview Temporal Decoupling via Circadian Clock Reset starts from the claim that modulating CLOCK within
Score: 0.543 · metabolic-neuroscience · 2026-04-20
## Mechanistic Overview Circadian Epigenetic Ketone Synchronization Protocol starts from the claim that modulating CLOCK
Score: 0.524 · neurodegeneration · 2026-04-21
## Mechanistic Overview Circadian Clock Epigenetic Desynchronization Window starts from the claim that modulating BMAL1/
Score: 0.455 · chronobiology · 2026-04-27
Timed delivery of NAD+ precursors and AMPK activators to reset microglial circadian metabolism from glycolytic pro-infla
Score: 0.455 · chronobiology · 2026-04-27
Timed delivery of MMP inhibitors to modulate extracellular environment maintaining microglial priming, allowing circadia
Score: 0.455 · chronobiology · 2026-04-27
Targeted viral delivery of circadian transcription factors specifically to microglia to restore cell-autonomous circadia
Score: 0.455 · memory-and-navigation · 2026-04-27
ADCY8's role in memory-based navigation may involve coupling spatial memory consolidation to circadian rhythms. Therapeu
Score: 0.455 · spatial-memory · 2026-04-27
Migration routes are maintained through coupling of circadian rhythms with spatial memory networks. Restoring disrupted